These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29432897)

  • 1. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
    Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
    Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
    Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
    Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
    Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
    J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics aspects of oral anticoagulants therapy.
    Militaru FC; Vesa SC; Pop TR; Buzoianu AD
    J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
    Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
    Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene.
    Wzorek J; Wypasek E; Awsiuk M; Potaczek DP; Undas A
    Blood Coagul Fibrinolysis; 2018 Jul; 29(5):429-434. PubMed ID: 29794812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.
    Nowak-Göttl U; Dietrich K; Kruempel A; Geisen C; Mitchell LG
    Blood Cells Mol Dis; 2017 Sep; 67():54-58. PubMed ID: 28284562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.
    Eriksson N; Wallentin L; Berglund L; Axelsson T; Connolly S; Eikelboom J; Ezekowitz M; Oldgren J; Paré G; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Yusuf S; Wadelius M
    Pharmacogenomics; 2016 Aug; 17(13):1425-39. PubMed ID: 27488176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.